CD1-CM119 | 价格

CD1-CM119-100μg / 询价

CD1-CM119-500μg / 询价

CD1-CM119-500μgx2 / 询价

Cynomolgus/Rhesus macaque CD19 Protein

产品信息(Product Info)
表达区间及表达系统(Source)

Recombinant Cynomolgus/Rhesus macaque CD19 Protein is expressed from HEK293 with His tag at the N-terminus
It contains Gln21-Trp291 [Accession | A0A2K5W8L9].

分子量大小(Molecular Weight)

The protein has a predicted MW of 30.96 kDa. Due to glycosylation, the protein migrates to 50-70 kDa based on Bis-Tris PAGE result.

纯度(Purity)

>95% as determined by Bis-Tris PAGE

内毒素(Endotoxin)

Less than 1 EU per μg by the LAL method.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.

重构方法(Reconstitution)

Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.

存储(Storage)

-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

产品数据(Assay Data)
Bis-Tris PAGE

Cynomolgus/Rhesus macaque CD19 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SPR Data

Anti-CD19 Antibody, hFc Tag captured on CM5 Chip via Protein A can bind Cynomolgus/Rhesus macaque CD19, His Tag with an affinity constant of 0.46 μM as determined in SPR assay (Biacore T200).

背景(Background)

CD19 is a 95 kDa transmembrane glycoprotein that plays a central role in B cell activation and humoral immune responses. Functions as coreceptor for the B-cell antigen receptor complex (BCR) on B-lymphocytes. Decreases the threshold for activation of downstream signaling pathways and for triggering B-cell responses to antigens. Activates signaling pathways that lead to the activation of phosphatidylinositol 3-kinase and the mobilization of intracellular Ca2 stores.

分子别名(Synonyms)

CD19; B4; CVID3; Leu-12; MGC12802

文献(References)

Maude S L, Teachey D T, Porter D L, et al. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia[J]. Blood, 2015, 125(26):4017-23.